It follows that the presence of PIK3CA mutations is being exploited as a predictive marker of benefit as indicated in a recent clinical trial of PI3K/Akt/mTOR inhibitors on patients with advanced cancers, where a higher response rate was observed in patients with the mutation as compared to those without79, 80, 81. This evidence concerns the gene MTOR and cancer.